COPD Co-infection With Tuberculosis on Th17 Cell Differentiation

Completed

• Conditions: Tuberculosis Infection; Chronic Obstructive Pulmonary Disease
• Interventions: Other: No intervention

• Registration Number: NCT04966052
• Lead Sponsor: Peking University Third Hospital

Brief Summary

This project will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of factors such as TNF-α, IFN-γ and IL-17 in pulmonary blood and alveolar lavage fluid.

Detailed Description

Chronic obstructive pulmonary disease (COPD) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in COPD and tuberculosis, and there is an interaction between COPD and tuberculosis, but the exact mechanism is not clear. Pre-existing TB infection is an independent risk factor for COPD and can aggravate pulmonary function and increase hospitalization and mortality in COPD patients. In COPD patients, Th1 and Th17 cells are involved in the development of COPD and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (MMPs) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as TNF-α, IFN-γ, IL-17 are involved in the mechanism of their destruction, IL-17 restricts the expression of HIF-1α to inhibit the development of TB granulomas, and CT analysis revealed that combined TB exacerbates emphysema in COPD patients. The above evidence suggests that tuberculosis plays an important role in the formation of emphysema in COPD. In this project, we will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of TNF-α, IFN-γ, and IL-17 in pulmonary blood and alveolar lavage fluid.

Study Timeline

• Study Start: 2018-04-01
• Primary Completion: 2020-04-01
• Study Completion: 2020-06-01
• Status Verified: 2020-07
• Study First Submitted: 2021-07-04
• Study First Submitted QC: 2021-07-14
• Last Update Submitted: 2021-07-14
• Study First Posted: 2021-07-19
• Last Update Posted: 2021-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Clinical diagnosis of COPD
• age ≧ 40

Read More

Exclusion Criteria

• Presence of other chronic respiratory diseases other than COPD, such as asthma, bronchiectasis, interstitial lung disease, etc.
• History of chest and lung surgery.
• History of malignancy.
• Autoimmune disease.
• Long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids.
• Mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests.
• Acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
COPD combined with TB group	No intervention	COPD combined with pulmonary TB infection

Primary Outcome Measures

Name	Time	Method
Differentiation of Th17 cells	Day 1	Distribution of T cell subtypes, including CD4+, CD8+ T cells and Th17 cells, in blood specimens and alveolar lavage fluid by flow cytometry

Trial Locations

Locations (1)

Peking University Third Hospital; 🇨🇳 Beijing, Beijing, China